SBIO ALPS Fund Services - ALPS Medical Breakthroughs ETF

$SBIO The ALPS Medical Breakthroughs ETF (SBIO) seeks to provide exposure to small- and mid-cap biotechnology companies with at least one drug in Phase II or Phase III clinical trials. By focusing on this critical stage of the drug development pipeline, the fund targets companies with significant growth potential as they approach regulatory approval. Why You Might Want to Own SBIO Investors seeking high growth potential within the healthcare sector may find SBIO attractive as a way to gain exposure to the next generation of medical breakthroughs. The ETF provides exposure to firms that are often acquisition targets by larger pharmaceutical companies, adding potential upside beyond organic growth.